secwatch.observer — SEC 8-K summary
======================================

Issuer:     Taysha Gene Therapies, Inc. (TSHA)
CIK:        0001806310
Form:       8-K
Filed at:   2023-09-19T23:59:59+00:00
Accession:  0001193125-23-237632
Event type: other_material
Sentiment:  negative
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Taysha discontinues TSHA-120 in GAN; extends cash runway to Q4 2025 for TSHA-102
--------------------------------------------------------------------------------

- Taysha discontinues TSHA-120 for giant axonal neuropathy after FDA Type C feedback cited study design challenges for BLA.
- Astellas Gene Therapies declined its option to license TSHA-120.
- Cash runway extended into Q4 2025 by prioritizing TSHA-102 for Rett syndrome.
- Ongoing REVEAL Phase 1/2 trial for TSHA-102 in adults; pediatric trial planned.
- Taysha to pursue external strategic options for TSHA-120 to enable further development.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1806310/000119312523237632/0001193125-23-237632-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1806310/000119312523237632/d511672d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-237632

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer